[Comorbidities affecting abiraterone treatment in patients with metastatic castration-resistant prostate cancer: a meta- analysis].

Barna Budai, Bertalan Fekete, Krisztina Biró, Enikő Lénárt, Attila Patócs, Lajos Géczi

Abstract readEnglish AbstractMeta-Analysis

In one paragraph

Synthesis in Magyar onkologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Barna BudaiMolekuláris Genetikai Osztály, Országos Onkológiai Intézet, Budapest, Hungary. budai.barna@oncol.hu.

Bertalan FeketeII. Belgyógyászati Osztály, Észak-Pesti Centrumkórház-Honvédkórház, Budapest, Hungary.

Krisztina BiróUrogenitális Tumorok és Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.

Enikő LénártUrogenitális Tumorok és Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.

Attila PatócsMolekuláris Genetikai Osztály, Országos Onkológiai Intézet, Budapest, Hungary. budai.barna@oncol.hu.

Lajos GécziUrogenitális Tumorok és Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimOptimizing the treatment of metastatic prostate cancer is important for reducing mortality. Therefore, it is essential, among others, to know the predictive markers of abiraterone acetate (AA) treatment in metastatic castration-resistant prostate cancer (mCRPC). We aimed to clarify the predictive factors of AA treatment of mCRPC patients, and particularly the predictive role of comorbidities and co-medication based on meta-analysis of published data.

methodsMeta-analysis of the results of multivariate analysis found in 120 publications examining at least 100 cases.

resultsBesides clear predictors of progression-free and overall survival, opioid use, pain, cerebrovascular diseases, dyslipidemia, statin treatment, bisphosphonate/antiresorptive treatment and metabolic syndrome significantly affect the risk of progression and survival.

conclusionsSince the analysis of comorbidities is based on relatively few observations, further studies are needed to clarify the predictive impact of comorbidities and co-medication in order to improve the effectiveness of treatment in mCRPC in an individualized manner.

Indexed as

Abiraterone AcetateAntineoplastic AgentsProstatic Neoplasms, Castration-ResistantAnalgesics, OpioidAndrostenesBone Density Conservation AgentsComorbidityDiphosphonatesDisease ProgressionDyslipidemiasHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMetabolic SyndromeNeoplasm MetastasisProgression-Free SurvivalabirateroneAbiraterone AcetateAnalgesics, OpioidAndrostenesAntineoplastic AgentsBone Density Conservation AgentsDiphosphonatesHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID41819062

PMCPMC12990081

What OpenQuestion holds

Texttitle and abstract

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.